European Journal of Neurology · 2004 · 200 citations · 9 references
PharmacyPharmacologyPharmacotherapyBioavailabilityClinical PharmacologyPharmacovigilanceHeadache AssessmentHeadache ManagementMigraine PharmacotherapyHeadache Frequency AssessmentHeadache ProphylaxisLong-term ProphylaxisMigraine ProphylaxisPreventive Headache TherapyPreventive Migraine TherapyPreventive Migraine TreatmentRiboflavin Supplementation
The aim of this study was to investigate the efficacy of riboflavin for the prevention of migraine. An open label study was performed in a specialized outpatient clinic. Patients received 400 mg riboflavin capsules per day. Headache frequency, duration, intensity and the use of abortive drugs were recorded at baseline and 3 and 6 months after treatment. Headache frequency was significantly reduced from 4 days/month at baseline to 2 days/month after 3 and 6 months (P < 0.05). The use of abortive drugs decreased from 7 units/month to 4.5 units/month after 3 and 6 months of treatment (P < 0.05). In contrast, headache hours and headache intensity did not change significantly. We could demonstrate a significant reduction of headache frequency following riboflavin treatment. In addition, the number of abortive anti-migraine tablets was reduced. In line with previous studies our findings show that riboflavin is a safe and well-tolerated alternative in migraine prophylaxis.
9
F Sorge, Roberto De Simone, Enrico Marano et al. · Cephalalgia · 1988 · 3.5K citations
<sup>31</sup> P‐Magnetic resonance spectroscopy in migraine without aura
P. Montagna, Pietro Cortelli, L. Monari et al. · Neurology · 1994 · 124 citations · Full text